Health-related quality of life in cancer immunotherapy: a systematic perspective, using causal loop diagrams

被引:13
作者
Beaulieu, Elizabeth [1 ]
Spanjaart, Anne [2 ]
Roes, Ashley [1 ]
Rachet, Bernard [3 ]
Dalle, Stephane [4 ]
Kersten, Marie Jose [2 ]
Maucort-Boulch, Delphine [5 ]
Jalali, Mohammad S. [1 ,6 ]
机构
[1] Harvard Med Sch, MGH Inst Technol Assessment, Boston, MA 02115 USA
[2] Univ Amsterdam, Canc Ctr Amsterdam, Dept Hematol, Amsterdam UMC, Amsterdam, Netherlands
[3] London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London, England
[4] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Dept Dermatol, Pierre Benite, France
[5] Hosp Civils Lyon, Dept Biostat, Lyon, France
[6] MIT, Sloan Sch Management, 77 Massachusetts Ave, Cambridge, MA 02139 USA
关键词
Immunotherapy; Cancer; Quality of life; Systems science; END-POINTS; OUTCOMES; LYMPHEDEMA; IMPACT; DRUG;
D O I
10.1007/s11136-022-03110-5
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Purpose System science offers a unique set of tools, including causal loop diagrams (CLDs), for stakeholders to better grasp the complexity of factors surrounding quality of life. Because the health-related quality of life (HRQoL) of cancer immunotherapy patients exists within an intricate system affected by and affecting many factors across multiple dimensions, the development of a systems-level model can provide a powerful framework to aid the understanding of this complexity. We developed a CLD for HRQoL of cancer immunotherapy patients. Methods We first applied a literature-based approach to construct a CLD for patients following immunotherapy. We then iteratively reviewed and enhanced the CLD through interviews with subject matter experts. Results Based on the reviewed literature and subject matter expert input, we produced a CLD representing the system surrounding cancer immunotherapy patients' HRQoL. Several feedback loops are identified that span clinical experiences, oncology teams' perceptions about immunotherapy, social support structures, and further research and development in cancer immunotherapy, in addition to other components. The CLD enables visualization of thought experiments regarding how a change anywhere in the system can ultimately worsen or improve patients' HRQoL. Conclusion The CLD illustrates the valuable contribution of a systems perspective to quality-of-life research. This systems-based qualitative representation gives insight on strategies to inhibit harmful effects, enhance beneficial effects, and inherent tradeoffs within the system. The CLD identifies gaps in the literature and offers a communication tool for diverse stakeholders. Our research method provides an example for studying the complexities of quality of life in other health domains.
引用
收藏
页码:2357 / 2366
页数:10
相关论文
共 67 条
  • [1] Health-related quality of life in cancer patients treated with PD-(L)1 inhibitors: a systematic review
    Abdel-Rahman, Omar
    Oweira, Hani
    Giryes, Anwar
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (12) : 1231 - 1239
  • [2] Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity
    Anagnostou, Valsamo
    Yarchoan, Mark
    Hansen, Aaron R.
    Wang, Hao
    Verde, Franco
    Sharon, Elad
    Collyar, Deborah
    Chow, Laura Q. M.
    Forde, Patrick M.
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (17) : 4959 - 4969
  • [3] [Anonymous], 2013, DELIVERING HIGH QUAL, DOI [10.17226/18359, DOI 10.17226/18359]
  • [4] Ashing-Giwa K., 2008, APPL RES QUAL LIFE, V3, P215, DOI DOI 10.1007/S11482-009-9057-Y
  • [5] The contextual model of HRQoL: A paradigm for expanding the HRQoL framework
    Ashing-Giwa, KT
    [J]. QUALITY OF LIFE RESEARCH, 2005, 14 (02) : 297 - 307
  • [6] Lower Body Lymphedema in Patients with Gynecologic Cancer
    Biglia, Nicoletta
    Zanfagnin, Valentina
    Daniele, Alberto
    Robba, Elisabetta
    Bounous, Valentina E.
    [J]. ANTICANCER RESEARCH, 2017, 37 (08) : 4005 - 4015
  • [7] Ipilimumab First Global Approval
    Cameron, Fiona
    Whiteside, Glenn
    Perry, Caroline
    [J]. DRUGS, 2011, 71 (08) : 1093 - 1104
  • [8] Cancer Research Institute, IMM TREATM TYP
  • [9] An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate
    Chen, Emerson Y.
    Raghunathan, Vikram
    Prasad, Vinay
    [J]. JAMA INTERNAL MEDICINE, 2019, 179 (07) : 915 - 921
  • [10] The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
    Cohen, Ezra E. W.
    Bell, R. Bryan
    Bifulco, Carlo B.
    Burtness, Barbara
    Gillison, Maura L.
    Harrington, Kevin J.
    Quynh-Thu Le
    Lee, Nancy Y.
    Leidner, Rom
    Lewis, Rebecca L.
    Licitra, Lisa
    Mehanna, Hisham
    Mel, Loren K.
    Raben, Adam
    Sikora, Andrew G.
    Uppaluri, Ravindra
    Whitworth, Fernanda
    Zandberg, Dan P.
    Ferris, Robert L.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7